Insight Molecular Diagnostics Inc. (IMDX) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $129.16M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | Joshua Riggs |
| IPO Date | 2015-12-30 | CAGR | — |
| Employees | 57 | Website | imdxinc.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $187.32M | P/E | -2.68 | Forward P/E | -5 | PEG | — |
| P/S | 12.37 | P/B | -1.11 | P/CF | -0.87 | P/FCF | -0.7 |
| Sales | $1.67M | Sales 1Y | -60.77% | Sales 3Y | 51.68% | Sales 5Y | -60.35% |
| EPS | $-1.49 | EPS 1Y | -56.27% | EPS 3Y | -84.65% | EPS 5Y | -79.15% |
| Sales QoQ | 646.88% | EPS QoQ | 158.33% | Sales QoQ Avg | 209.49% | EPS QoQ Avg | 51.67% |
| Gross Margin | 11.17% | Operating Margin | -2558.74% | Profit Margin | -2955.63% | ROCE | -223.06% |
| ROA | -168% | ROE | 272% | Altman Z Score | -23.19 | Piotroski Score | 1 |
| Current Ratio | 2 | Quick Ratio | 1.98 | Cash Ratio | 1.73 | Op. CF Ratio | -0.9 |
| Debt/Equity | -0.12 | Debt/Assets | 0.09 | Lt Debt/Equity | -0.04 | Lt Debt/Cap. | -0.04 |
| Intrst Cov. | -436.03 | Inventory Turnover | 7.17 | Asset Turnover | 0.06 | Receivables Turnover | 8.7 |
| Enterprise Value | $187.32M | P/E Ratio | -2.68 |
| Forward P/E | -5 | PEG Ratio | — |
| P/S Ratio | 12.37 | P/B Ratio | -1.11 |
| P/CF Ratio | -0.87 | P/FCF Ratio | -0.7 |
| EPS | $-1.49 | EPS Growth 1Y | -56.27% |
| EPS Growth 3Y | -84.65% | EPS Growth 5Y | -79.15% |
| Revenue Growth 1Y | -60.77% | Gross Margin | 11.17% |
| Operating Margin | -2558.74% | Profit Margin | -2955.63% |
| ROE | 272% | ROA | -168% |
| ROCE | -223.06% | Current Ratio | 2 |
| Quick Ratio | 1.98 | Cash Ratio | 1.73 |
| Debt/Equity | -0.12 | Interest Coverage | -436.03 |
| Altman Z Score | -23.19 | Piotroski Score | 1 |
Insight Molecular Diagnostics Inc. (IMDX) valuation & financials
Insight Molecular Diagnostics Inc. (IMDX) has a market capitalization of $129.16M and trades at a price-to-earnings ratio of -2.7. It operates in the Healthcare sector (Medical - Diagnostics & Research).
Insight Molecular Diagnostics Inc.'s revenue grew -60.8% over the last year.
Insight Molecular Diagnostics Inc.'s next earnings report is scheduled for November 9, 2026 after market close (provider scheduled date); analysts estimate EPS of $-0.24. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)
Insight Molecular Diagnostics Inc. revenue & earnings charts →